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HIV-1 Entry Inhibitors in the Side Pocket Minireview
transmembrane envelope glycoproteins. Most of the ex-Joseph G. Sodroski
Department of Cancer Immunology and AIDS posed surface of the assembled trimer is composed of
Dana-Farber Cancer Institute elements of gp120, with the gp41 ectodomain largely
Department of Pathology buried in the interior of the complex (Figure 1, left panel).
Harvard Medical School and The gp120 glycoprotein binds the host cell receptors,
Department of Immunology and Infectious Diseases whereas gp41 is thought to be responsible for fusing the
Harvard School of Public Health viral and target cell membranes. The gp41 ectodomain
Boston, Massachusetts 02115 must therefore be exposed to the target cell membrane
in a controlled fashion, when the virus has achieved
adequate proximity to the cell. Receptor binding not only
attaches and orients the viral envelope glycoproteins toSeveral years ago, investigators made the serendipitous
the target cell, but also triggers conformational changesdiscovery that peptides corresponding to segments of
in the envelope glycoproteins that promote the se-the human immunodeficiency virus (HIV-1) gp41 enve-
quence of events leading to membrane fusion. The na-lope glycoprotein could specifically and potently inhibit
ture of these conformational changes is imperfectly un-virus entry into target cells (Wild et al., 1992; Jiang et
derstood, as structural information is available on onlyal., 1993). Subsequently, the emergence of structural
a single conformation of gp120 (Kwong et al., 1998) andinformation on the HIV-1 envelope glycoproteins al-
gp41 (Chan et al., 1997; Tan et al., 1997; Weissenhornlowed insights into the mechanism by which these pep-
et al., 1997). CD4 binding has been shown to inducetides exert their antiviral effect. In addition to their use
a gp120 conformation that is able to bind the CCR5as tools to understand the process of HIV-1 entry, these
chemokine receptor with high affinity. A model in whichpeptides serve as a starting point for the development
chemokine receptor binding then results in the exposureof potentially useful therapeutics.
of the gp41 ectodomain is appealing, although the avail-HIV-1 Entry
able supporting data (Furuta et al., 1998) exhibit someHIV-1 enters cells through the interaction of its envelope
inconsistencies. For example, similar effects on gp41glycoproteins with cellular receptors, CD4 and chemo-
exposure were observed for both the CCR5 and CXCR4kine receptors (for review, see Chan and Kim, 1998;
chemokine receptors, even though only one of theseWyatt and Sodroski, 1998). Following receptor binding,
coreceptors supported gp120 binding and virus entrythe envelope glycoproteins fuse the viral membrane with
of the HIV-1 strains tested. Furthermore, the envelopethe target cell membrane, allowing entry of the viral core
glycoproteins of some HIV-1 strains exhibited the sameinto the host cell cytoplasm. Each envelope glycoprotein
gp41 exposure after binding only CD4, whereas chemo-spike on the viral surface consists of a trimer of three
gp120 exterior envelope glycoproteins and three gp41 kine receptor binding is necessary for the efficient entry
Figure 1. The HIV-1 Entry Process
The prefusogenic state of the trimeric HIV-1 envelope glycoproteins is depicted in the left panel. The HIV-1 receptors on the target cell, CD4
and the chemokine receptor CCR5, are shown.
Sequential binding of the HIV-1 gp120 glycoprotein to CD4 and then to CCR5 is believed to induce conformational changes in the envelope
glycoprotein complex. In the hypothetical intermediate depicted in the middle panel, the N36 coiled coil (blue) in the gp41 ectodomain is
present, and the hydrophobic gp41 amino termini (the ªfusion peptidesº) are interacting with the target cell membrane. The hydrophobic
grooves on the outer face of the N36 coiled coil are unoccupied and available for binding either the gp41 C34 helices (magenta) or dominant-
negative peptide inhibitors, one of which (magenta) is depicted on the left side of the figure.
The panel on the right depicts the association of the C34 helices (magenta) and the N36 coiled coil (blue), resulting in the approximation of
the viral and target cell membranes.
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of all known HIV-1 isolates. Additional work will be re-
quired to understand the contribution of chemokine re-
ceptor binding to entry-related conformational changes.
Conformational Changes in gp41
Despite uncertainties about how chemokine receptor
binding promotes the membrane fusion process, it is
likely that gp41 undergoes conformational changes from
an as-yet-undefined prefusogenic state to one that me-
diates membrane fusion (Figure 1, middle panel). The
latter state probably corresponds to the structures ob-
served for fragments of the HIV-1 gp41 ectodomain
(Chan et al., 1997; Tan et al., 1997; Weissenhorn et al.,
1997). In these extremely stable and therefore energeti-
cally favored structures, a gp41 region, herein referred
to as N36, forms a trimeric, a-helical coiled coil. N36 is
immediately C-terminal to the hydrophobic gp41 amino
terminus, which is thought to interact with the target
cell membrane and hence is called the fusion peptide.
In the fusogenic conformation, a gp41 region, herein
referred to as C34, packs into the well-conserved,
largely hydrophobic groove on the outer surface of the Figure 2. Potential Targets on the HIV-1 gp41 Coiled Coil
N36 coiled coil to create a six-helix bundle. Because A detailed structure of the putative fusogenic conformation of the
C34 is located near the viral membrane, the formation HIV-1 gp41 glycoprotein is shown. The structure is oriented as in
of this structure results in the approximation of the viral Figure 1, with the target cell membrane at the bottom of the figure.
The molecular surface of the N36 coiled coil is shown in blue andmembrane and the target cell membrane (Figure 1, right
yellow. The packing of the C34 helix (magenta and green) into thepanel). The notion that the six-helix bundle represents
hydrophobic groove on the surface of the N36 coiled coil is evident.
a fusion-active gp41 conformation is supported by the The surface of the N36 pocket is colored yellow, and the C34 resi-
observation that similar structures have been observed dues contacting the pocket are colored green. The approximate
in the glycoproteins of other enveloped viruses and in regions of the C34 helix mimicked by dominant-negative inhibitors
of the N36±C34 interaction are depicted on the right side of thecellular SNARE proteins, which also mediate membrane
figure. The DP178 peptide binds in the N36 groove, whereas thefusion (for review, see Chan and Kim, 1998; Skehel and
D10-pX-2K cyclic peptides bind in the N36 pocket.Wiley, 1998). For the influenza virus hemagglutinin, di-
rect X-ray crystallographic evidence exists for two con-
formational states, one prefusogenic and the other,
The gp41 Glycoprotein as a Target for Intervention
which is related to the HIV-1 gp41 six-helix bundle,
The interaction of the N36 and C34 sequences of the
thought to represent the fusogenic conformation. In
gp41 glycoprotein has been suggested as a potential
HIV-1, the evidence for the functional importance of
target for anti-HIV-1 therapy (Chan et al., 1997). Most
gp41 conformational changes is more indirect and is efforts in this direction have focused on analogs of the
based on the potent inhibitory activity of the gp41 pep- more potent C34 peptides. X-ray crystal structures
tides alluded to above. Peptides corresponding to both (Chan et al., 1997; Tan et al., 1997; Weissenhorn et al.,
the N36 and C34 helices exhibit the specific ability to 1997) revealed that the surface of the N36 trimer that
inhibit HIV-1 infection, with the C34 peptides being more contacts the C34 helices consists of a long hydrophobic
potent (Wild et al., 1992; Jiang et al., 1993). It is thought groove. At one end of this groove is a 400 AÊ 3 pocket
that the C34 peptides act in a dominant-negative fash- that accommodates three hydrophobic C34 residues,
ion, packing into the grooves of the N36 coiled coil and isoleucine 635, tryptophan 631, and tryptophan 628 (Fig-
preventing the natural C34 region on gp41 from doing ure 2). In addition, one of the N36 pocket-lining residues,
so (Figure 1, middle panel). This model of inhibition is lysine 574, forms a salt bridge with aspartic acid 632 of
supported by the correlation between the ability of mu- the C34 helix. Some C34-like peptides that lack these
tant C34 peptides to bind the N36 coiled coils and virus- pocket-contacting residues still exhibit reasonably po-
inhibiting activity (Chan et al., 1998). Furthermore, in tent anti-HIV-1 activity (for example, see DP178 in Table
tissue culture, viruses can develop resistance to C34 1). However, it is easier to generate HIV-1 variants in
peptides by altering N36 sequences that contact the tissue culture resistant to the DP178 peptide than to
C34 helix in the six-helix bundle (Rimsky et al., 1998). peptides that retain the ability to bind the N36 pocket
That an exogenous C34 peptide can efficiently compete (Rimsky et al., 1998). The DP178 peptide, also called
for the natural gp41 C34-like sequence is an argument T20, was administered intravenously to groups of HIV-
that, in some conformation that exists prior to the fuso- 1-infected individuals, each of which received a different
genic state, the N36 coiled coil is both formed and ac- dose, for a 14-day period (Kilby et al., 1998). The four
cessible. C34-like peptides do not bind the prefusogenic subjects who received the highest dose (100 mg twice
HIV-1 envelope glycoprotein trimer (Furuta et al., 1998), daily) exhibited a 1.96 log10 median decline in plasma
arguing for the existence of a C34-binding intermediate viral RNA, a level of inhibition comparable to that seen
between prefusogenic and fusogenic forms of the HIV-1 for currently used reverse transcriptase or protease in-
hibitors administered as single agents. The safety andenvelope glycoproteins.
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Table 1. HIV-1 Entry Inhibitors Targeting the N36 Coiled Coil of the gp41 Glycoprotein
Inhibitory Concentration
Target on the N36 (IC50) for HIV-1 Entry or
Inhibitor Description Coiled Coil Cell-Cell Fusion
C34 34-residue peptide Hydrophobic groove and pocket 2±5 nM
DP178 (T20) 36-residue peptide Hydrophobic groove only 50±60 nM
P30 30-residue peptide Hydrophobic groove only 7 mM
C7-Mn34-Mn42-P30 30-residue peptide with Hydrophobic groove and pocket 0.3 mM
non-peptide elements
D10-pX-2K 16- to 18-residue cyclic Pocket only 3±200 mM
D-peptides
short-term efficacy of the T20 peptide demonstrates that, sequences, and several of these were synthesized using
D±amino acids (ªD10-pX-2Kº peptides) and tested. Thein principle, the functional interactions between two ele-
ments of the gp41 glycoprotein represent as efficient a D10-pX-2K peptides inhibited syncytium formation in-
duced by the HIV-1 envelope glycoproteins and HIV-1target as the HIV-1 enzymes, reverse transcriptase and
protease. entry in the micromolar range. X-ray crystallographic
and NMR studies verified that the D10-pX-2K peptidesTargeting the N36 Pocket
The initial encouraging clinical results with the T20 pep- bind the N36 pocket. The D10-pX-2K peptides assume
a generally circular structure as a result of intrachaintide support efforts to create more biologically available
and potent inhibitors of HIV-1 gp41 function. Com- disulfide bond formation, with a left-handed helix on the
peptide binding the pocket in an orientation similar topounds less than 400 daltons represent the vast majority
of clinically useful drugs, so decreasing the size of the that previously seen for the C34 helix. The D10-pX-2K
helix contributes four residues, including two tryptophaninhibitors would be desirable. In addition, foreign pep-
tides are potentially susceptible to proteolysis or im- residues, that are deeply buried in the hydrophobic N36
pocket. With the exception of one of these tryptophanmune clearance, and typically are not orally bioavailable.
One suggestion for designing smaller C34-like inhibitors residues, the pocket-binding residues of the D10-pX-
2K and C34 peptides occupy different positions, asis to target the pocket in the N36 surface rather than
the entire hydrophobic groove. C34 peptides altered in might be expected from the opposite handedness of
the two inhibitors.the residues contacting the pocket exhibit reductions in
binding affinity for N36 and decreased antiviral potency, These results clearly demonstrate the feasibility of
targeting the gp41 N36 pocket to inhibit HIV-1 envelopesupporting the importance of interactions within the
pocket to N36±C34 association (Chan et al., 1998). Alter- glycoprotein function. A further reduction in size of the
D10-pX-2K peptides will likely be necessary to createation of gp41 N36 residues that line the pocket or C34
residues that contact the pocket in the fusogenic confor- a clinically practical therapeutic. Furthermore, the D10-
pX-2K peptides exhibit lower antiviral potency than themation results in nonfusogenic envelope glycoproteins
(Cao et al., 1993; Dubay et al., 1992). These results justify longer C34-like peptides, an expected consequence of
contacting a smaller surface on the gp41 target. Tothe expectation that disrupting the molecular interac-
tions within the pocket will result in inhibition of HIV-1 satisfy the dual requirements of potency and reduced
size, investigators will probably need to exploit the po-entry.
The attractiveness of the N36 pocket as a drug target tential of nonpeptide molecules to fill the N36 pocket
more efficiently than the natural C34 residues.has been underscored by the recent elegant work of Kim
and colleagues (Eckert et al., 1999). These investigators The creation of soluble forms of the N36 trimer (Eckert
et al., 1999; Ferrer et al., 1999) opens the door to thesuccessfully identified D±amino acid peptide inhibitors
that bind exclusively to the N36 pocket and demon- use of a wide variety of empirical methods to identify
potential nonpeptide inhibitors of the N36-C34 interac-strated the antiviral activity of these molecules. To cre-
ate a target that would be useful in screening for these tion. Screening of combinatorial chemical libraries of
nonnatural molecules coupled to segments of C34-likeinhibitors, the tendency of N36 peptides to aggregate
in the absence of C34-like peptides had to be overcome. peptides has recently been employed to identify new
moieties that interact with the N36 pocket (Ferrer et al.,This was accomplished by fusing the C-terminal half of
N36 to a trimeric version of the GCN4 transcription factor 1999). The C34-like peptides used in this case bound
with low affinity to the hydrophobic groove on the solu-and by modifying several hydrophobic residues pre-
dicted to be surface exposed. Eckert et al. used the ble N36 trimer, and potential pocket-interactive ele-
ments were identified by demanding a higher affinity.resulting soluble mimic of the N36 pocket, designated
IQN17, in a mirror-image phage display approach (Schu- The selected elements, designated C7-Mn34-Mn42,
contributed to the potency of a 30-residue C34-like pep-macher et al., 1996) to identify peptide-based inhibitors
that target the pocket. The mirror image of IQN17 and tide in inhibiting cell-cell fusion mediated by the HIV-1
envelope glycoproteins (compare C7-Mn34-Mn42-P30control molecules altered in the pocket were synthe-
sized using D±amino acids. These molecules were then and P30 in Table 1). Although the currently identified
nonnatural elements appear to interact with the N36used to screen a phage library expressing peptides of
ten random residues flanked by either cysteines or ser- pocket less efficiently than the natural C34 residues
(Ferrer et al., 1999), it can be anticipated that futureines. The selected phage exhibited consensus peptide
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detailed structures of these inhibitors complexed with
N36 trimers will assist the development of more potent
pocket-filling molecules.
Future Considerations
As inhibitors of the gp41 conformational change un-
dergo more extensive clinical testing, we can anticipate
that, as for all other antiretroviral agents studied to date,
virus variants exhibiting some degree of drug resistance
will emerge. Viruses selected in tissue culture systems
to be resistant to C34 peptides exhibit changes in the
hydrophobic groove of the N36 trimer, not in the pocket
(Rimsky et al., 1998). Indeed, the pocket-lining residues
are well conserved among primate immunodeficiency
viruses, providing hope that any resistant virus variants
will be significantly reduced in fitness. However, the
viral capacity for variation in this structure may only be
revealed once the selective pressure associated with
pocket-specific inhibitors is applied. The potential co-
evolution of complementary N36 and C34 gp41 regions
creates a greater number of opportunities for the devel-
opment of resistance. The wealth of new knowledge about
gp41 structure and function, and about HIV-1 entry in
general, should assist efforts to address these chal-
lenges. Therapeutic additions to our current armamen-
tarium of antiretroviral agents would be most welcome.
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